You are here

Treatment Persistence for Infliximab Versus Adalimumab in Crohn’s Disease: A 14-Year Single-Center Experience.

Treatment Persistence for Infliximab Versus Adalimumab in Crohn’s Disease: A 14-Year Single-Center Experience. Inflamm Bowel Dis. 2017 Mar 16;: Authors: Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-Biroulet L Abstract BACKGROUND: Infliximab (IFX) and adalimumab (ADA) are widely used in the treatment of patients with Crohn’s disease (CD). There are few published data on the treatment persistence of IFX and ADA in patients with CD. METHODS: We aimed to compare the persistence rates of IFX versus ADA as first- and second-line tumor necrosis factor antagonist (anti-TNF), to…

Read More

The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.

The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Mar 20;: Authors: Seow CH, Leung Y, Vande Casteele N, Ehteshami Afshar E, Tanyingoh D, Bindra G, Stewart MJ, Beck PL, Kaplan GG, Ghosh S, Panaccione R Abstract BACKGROUND: Transplacental transfer of infliximab and adalimumab results in detectable drug levels in the cord blood and infant. AIM: To determine if pregnancy influenced the pharmacokinetics of anti-TNF agents in women with inflammatory bowel disease. METHODS: Twenty-five women from the University of Calgary…

Read More

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease.

Related Articles Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease. World J Gastroenterol. 2017 Feb 28;23(8):1489-1496 Authors: Oh EH, Ko DH, Seo H, Chang K, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH Abstract AIM: To investigate the clinical implications of infliximab trough levels (IFX-TLs) and antibodies to infliximab (ATI) levels in Crohn’s disease (CD) patients in Asian countries. METHODS: IFX-TL and ATI level were measured using…

Read More

Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.

Related Articles Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months. Dig Dis Sci. 2017 Mar 09;: Authors: Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro D, Benítez Roldán A, Merino V, Ramírez G, Caunedo Álvarez A, Romero Gómez M Abstract BACKGROUND: CT-P13 is a biosimilar of Remicade(®), an agent approved in some countries for use in inflammatory bowel disease (IBD). Controlled clinical trials have demonstrated the efficacy and safety of CT-P13…

Read More

Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.

Related Articles Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017 Feb 26;: Authors: Komaki Y, Yamada A, Komaki F, Micic D, Ido A, Sakuraba A Abstract BACKGROUND: Biosimilars of anti-tumour necrosis factor (TNF)-α agents have now become clinically available for the treatment of inflammatory bowel diseases (IBD). AIM: We performed a systematic review and meta-analysis to evaluate the efficacy and safety of biosimilars of anti-TNF-α agents in patients with IBD. METHODS: Electronic…

Read More

Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.

Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Feb 23;: Authors: Strik AS, van den Brink GR, Ponsioen C, Mathot R, Löwenberg M, D’Haens GR Abstract BACKGROUND: Loss of response to anti-tumour necrosis factor (TNF) therapy in patients with inflammatory bowel disease (IBD) is often caused by anti-drug antibody formation with neutralisation of drug effect. Addition of an immunomodulator has been suggested to reduce immunogenicity, leading to regained response. AIM: To investigate whether addition…

Read More

Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease.

Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017 Feb 17;: Authors: Yarur AJ, Kanagala V, Stein DJ, Czul F, Quintero MA, Agrawal D, Patel A, Best K, Fox C, Idstein K, Abreu MT Abstract BACKGROUND: Infliximab has been found to be efficacious in the treatment of fistulas in the setting of Crohn’s disease, even though some patients do not benefit from therapy. AIM: To assess the correlation between perianal fistula healing and trough levels of infliximab. METHODS: In this…

Read More
<< Go Back